Posted by Michael Wonder on 10 Oct 2022
Nanoscope Therapeutics receives fast track designation by the FDA for MCO-010 for the treatment of retinitis pigmentosa
10 October 2022 - Nanoscope Therapeutics today announced that the US FDA has granted fast track designation to MCO-010, an ambient-light activatable multi-characteristic opsin optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa via intravitreal injection.
In January 2022, 27 retinitis pigmentosa patients with advanced vision loss were enrolled in a multi-centre, randomised, double-masked, sham controlled RESTORE clinical trial of MCO-010.
